tbuckley/cabot-search huggingface dataset:
417P EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project
Authors: C. Omarini, V. Catani, A. Toss, I. Mastrolia, F. Banchelli, O. Ponzoni, M. Brucale, F. Valle, M.C. Baschieri, V. Masciale, R. D'Amico, F. Piacentini, M. Dominici
Journal: Annals of Oncology (2024)
457P Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Authors: J.G. Yaringaño Cerna, O. Mirallas, D.A. Gomez Puerto, G. Velilla, V. Navarro Garces, T. Gorría Puga, A.M. Monino, M.Á. Vaz-Salgado, D. Lopez-Valbuena, A. Hernandez Gonzalez, M. Aguado Sorolla, M. Gonzalez Rodriguez, M. Martínez-García, J.C. Galceran, C. Balana, G. Villacampa, R. Dienstmann, E. Pineda, J.M. Sepúlveda, M. Vieito
Journal: Annals of Oncology (2024)
380P Assessing interstitial lung disease (ILD) risk in metastatic breast cancer (MBC): A comprehensive meta and network analysis of antibody-drug conjugates (ADCs) compared to available treatment options beyond first-line (1L)
Authors: L. Cucciniello, F. Giudici, P. Di Nardo, A. Dri, S. Della Rossa, E. Zottarelli, C. Noto, L. Foffano, B. Pastò, S. Bolzonello, L. Da Ros, G. Cudia, E. Nascimbeni, C. Lisanti, S. Spazzapan, D. Serraino, L. Gerratana, F. Puglisi
Journal: Annals of Oncology (2024)
460P Exploring the efficacy and optimal timing of tumor treating fields in newly diagnosed glioblastoma: A real-world study
Authors: Z. Dai, Y. Liu, J. Yin, Y. Zhang, R. Qiu, G. Li, R. Liu, X. Li, D. Liu, H. Li, X. Zhang, F. Wang, X. Wang, P. Ai, Z. Li, Q. Mao, L. Liu
Journal: Annals of Oncology (2024)
492P Linking cellular drug responses to corresponding metabolomic tissue signatures in gliomas
Authors: S. Stanzer, J. Bandres-Meriz, N. Harbusch, J. Franz, K. Mahdy-Ali, F. da Silva Souza Monedeiro, C. Magnes, E. Zügner, T. Pieber, A. El-Heliebi, T. Urbanic, A. Woehrer, B. Prietl
Journal: Annals of Oncology (2024)
392P Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Authors: A.M. Brufsky, A. Bardia, M.S. Sedrak, S. Loibl, S.M. Tolaney, K. Punie, S.A. Hurvitz, K. Kalinsky, J. Cortés, J. O'Shaughnessy, V.C. Dieras, M. Piccart, A. Dasgupta, A.G. Kaushik, C. Lai, L. Shi, H.S. Rugo
Journal: Annals of Oncology (2024)
CN13 Impact of AI clinical trial program on screening, matching, and enrollment of patients over 6 months
Authors: D. Shepard, S. Mallahan, C. Osterman, D. Skelly, E. Patnaude, M. Weiss, B.H. O’Neil, A. Rao, N.E. Abdulla, A. Zarzour, K. Kumar Sankhala, M.G. Goldstein, B. Parsons, P. La Porte, A.G. Franzen, E. Cohen, M. Cooney
Journal: Annals of Oncology (2024)
333P Efficacy and cell-free DNA whole methylome based biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple negative breast cancer: A prospective multi-center cohort study
Authors: X. Chen, M. Xiu, H. Kang, Y. Zhang, Q. Li, X. Cheng, J. Wang, B. Lan, S. Chen, M. Xiao, X. Qian, B. Hua, B. Xu, P. Zhang
Journal: Annals of Oncology (2024)
378P Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
Authors: D.Y. Yang, T. Sun, Z-H. Chen, Q. Ouyang, K. Li, M. Yan, Z. Lv, Z. Li, L. Man, X. Luo, Y. Dong, M. Jing, None Y. wang, X. Guo, J. Xu, X. Li, C. Jiang, Y. E, L. Jiang, H. Cao
Journal: Annals of Oncology (2024)
471P PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma
Authors: E. Cella, M. Polano, M. Padovan, A. Bosio, M. Caccese, M. Corrà, G. Cerretti, E. Bennicelli, G. Toffoli, G. Lombardi
Journal: Annals of Oncology (2024)
476P The role of androgen receptor expression and epigenetic regulation in adult-type diffuse gliomas
Authors: V. Di Nunno, S. Asioli, L. Morandi, L. Gatto, A. Tosoni, S. Bartolini, L. Griva, S. Melotti, R. Lodi, M.P. Foschini, E. Franceschi
Journal: Annals of Oncology (2024)
414P The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Authors: B. Pastò, J-Y. Pierga, T.N. Fehm, J.Á. García Saenz, C. Caldas, P. Gazzaniga, A. Fernandez de Lascoiti, L. De Mattos-Arruda, M. Ignatiadis, D. Generali, S. Riethdorf, E-F. Solomayer, C. Reduzzi, M. Giuliano, F. Puglisi, W. Janni, L. Gerratana, K. Pantel, F.C. Bidard, M. Cristofanilli
Journal: Annals of Oncology (2024)
404P Real-world analysis on molecular targeted therapy recommendations and attainment rates in cancer gene panel testing for metastatic breast cancer
Authors: H. Tada, M. Miyashita, N.S. Harada, Y. Hamanaka, A. Ebata, M. Sato, T. Motonari, M. Yanagaki, A. Yamazaki, T. Kon, T. Ishida
Journal: Annals of Oncology (2024)
410P Breast cancer lighthouse non-interventional hybrid real-world study: Molecular characterization and 2-year effectiveness data
Authors: A.M. Nogal Dias, A.L.V. Matos, B.E. Gosalbez Pequeno, S. Braga, L.I. Pinto, A. Pego, C.D. Abreu, M.I.R. Ferreira, P.F. Gago, I. Faustino, I.M. Matos Pina, C.P. Marques, J.L.C. Passos-Coelho, F.P. Branco, J.C.D.L. Simões, I.V. Vaz Luis, F. Schmitt, L. Costa, M. Domingues, D. Bras
Journal: Annals of Oncology (2024)
338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Authors: M. Ignatiadis, E. Saloustros, A. Joaquim, J.G. Casas, C.M. Kelly, E. Razis, M. Lambertini, T. Foukakis, M. Fehr, C.W. Menke-van der Houven van Oordt, T. Antoniolli Crestani, S. Pernas Simon, B. Bussels, M. Hanssens, P. Neven, E. Xenophontos, T. Meyskens, F.C. Bidard, C. Poncet, W. Janni
Journal: Annals of Oncology (2024)
316P Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials
Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjöld, G. Pérez Tenorio, N.P. Tobin, B.A. Nordenskjöld, O. Stål, L. Esserman, L.J. Van't Veer, L.S. Lindström
Journal: Annals of Oncology (2024)
382P Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study
Authors: J. Liu, M. He, M. Jiang, S. Zhou, M. Zhang, Y. Li, S. Chen, R. Cai, H. Mo, B. Lan, F. Ma, B. Xu, Q. Li
Journal: Annals of Oncology (2024)
304P Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study
Authors: S. Sasada, Y. Takahashi, K. Terata, K. Kida, Y. Sagara, T. Ueno, K. Anan, A. Suto, C.K. Kanbayashi, None M. takahashi, R. Nakamura, T. Ishiba, M. Tsuneizumi, S. Nishimura, Y. Naito, F. Hara, H. Iwata, T. Shien
Journal: Annals of Oncology (2024)
332P Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab plus nab-paclitaxel followed by epirubicin/cyclophosphamide for TNBC: A phase II TREND trial
Authors: Y. Xu, M. Wang, Q. Zhang, Y. Li, H. Zhang, Y. Wang, L. Yao, H. Dong
Journal: Annals of Oncology (2024)
292P Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2– early breast cancer (EBC) from US electronic health records (EHR)
Authors: K. Jhaveri, M. Pegram, P. Neven, G. Curigliano, L.M. Spring, J. Gligorov, I. Schlam, N. Harbeck, D. Juric, E. Lim, S. Wang, H. Owusu, M. Akdere, F. Ye, J. Kim, F. Cardoso
Journal: Annals of Oncology (2024)
321P Sentinel lymph node biopsy in clinical T3-4c breast cancer: A retrospective multicenter cohort study
Authors: Y. Sagara, S. Kuba, S. Maeda, H. Yano, T. Sakai, Y. Kojima, M. Hattori, S. Asaga, E. Tokunaga, T. Shien, H. Bando, K. Anan, N. Iwakuma, M. Yamaguchi, M. Harao, M. Oikawa, T. Sangai, M. Ishitobi, T. Nakayama, N. Hayashi
Journal: Annals of Oncology (2024)
285P Adherence to endocrine therapy and sexual dysfunction in patients older than 65 years with early estrogen receptor-positive breast cancer
Authors: D.X. Assad, D.L. Dos Santos, H.M. Resende, F. Cesar Moura, S.C.S. Oliveira, A.K. Shimada, R. Arakelian, A.L. Galvão, B. Wance, A. Guimarães Castro, M.C.F.M.D. Andrade, Y. Cardoso Rodrigues Beckedorff Bittencourt, M.C.F. Magalhães, C. de Pádua Souza, C.E. Paiva, P. Signorini, D.J. Pereira, A.N. Rodrigues, D.D. Rosa, R. Barroso-Sousa
Journal: Annals of Oncology (2024)
263P Association between clinicopathological characteristics and pathological complete response in patients with triple negative breast cancer treated by neoadjuvant chemo-immunotherapy
Authors: C. Helal, L. Djerroudi, T. Ramtohul, E. Laas, A. Vincent-Salomon, M. Jin, R-D. Seban, I. Bieche, D. Bello Roufai, F.C. Bidard, P.H. Cottu, D. Loirat, M. Carton, F. Lerebours, N. Kiavue, E. Romano, C. Bonneau, L. Cabel
Journal: Annals of Oncology (2024)
25P NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Authors: E.S. Kuligina, A.P. Sokolenko, R.V. Broyde, R.S. Mulkidjan, M.V. Semina, A.A. Romanko, A.S. Martianov, J.A. Gorgul, A. Nostaeva, Y. Aulchenko, E.N. Imyanitov
Journal: Annals of Oncology (2024)
283P Immune-mediated secondary adrenal insufficiency is more commonly found in younger patients undergoing neoadjuvant treatment for early breast cancer
Authors: L.S. Lapuchesky, F.D. Waisberg, P. Mando, F. Urtasun, I. Robledo Salas, G. Colucci, M.A. Ipina, A. Borello, M.M. Morinigo Kober, A. Mazzotta, M.A. Nunell, M. Gill, G. Gomez-Abuin, C.R. Gallina Nanni, M.V. Costanzo, A.A. Nervo, E.P. Korbenfeld, M.V. Caceres, F. Perazzo, J.C. Nadal
Journal: Annals of Oncology (2024)
274P A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3
Authors: G. Dzagnidze, C. Morrow, T. Gogitidze, Z.S. Katashvili, J.E. Bargallo Rocha, E. Arkania, I. Moppett, K-L. Cheung, G. Nemsadze, M. Ajimi, K. Andreou, A. Chambers, D. Chain, R. Kim, J. Lindemann, R. Mcewen, M. Nikolaou, J. Robertson, D. Whitston, J.F. Robertson
Journal: Annals of Oncology (2024)
309P A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Interim analysis of the NER-Tree study
Authors: X. Wang, H. Liu, X. Liu, J. Gao, S. Ma, J. Ye, Y. Zhang, J. Wu, S. Zhang, Y. Wang, X. Wu, None J. ma, A. Zhang, Q. Ouyang, Y. Chen, J. Liu, None H. zhang, G. Jiang, Z. Niu, J. Zhang
Journal: Annals of Oncology (2024)
356P Real-world effectiveness in subgroups of palbociclib + endocrine therapy in HR+/HER2- ABC patients: Interim results of the PERFORM study
Authors: G. Pfeiler, M. Korell, J.C. Radosa, T. Decker, M. Deryal, T.J. Fietz, A. Köhler, B. Schöttker, J. Wilke, J. Knoblich, V. Petersen, M. Dietrich, T. Gabrysiak, H. Krueger, E. Zanucco, A. Adams, M. Glasstetter, S.M. Woerner, R. Bartsch, M.P. Lux
Journal: Annals of Oncology (2024)
269P Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
Authors: B. Pellegrino, C. Tornali, A. Lazzarin, B. Cotelli, A. Ingallinella, N. Campanini, C. Tommasi, M. Corianò, O. Serra, M. Michiara, D. Boggiani, A. Schirone, C. Casarini, E. Cretella, G. Zoppoli, M. Lambertini, M. Botosso, L. Cortesi, E.M. Silini, A. Musolino
Journal: Annals of Oncology (2024)
46P The comparison outcome of GEMOX and PD-1 inhibitors combined with or without lenvatinib for advanced intrahepatic cholangiocarcinoma (ICC): A prospective, single-center, open-label, double-arm phase II trial
Authors: N. Zhang, K. Liu, Y. Huo, X. Liu, S. Zhang, W. Zhu, T. Liu, H. Yu, Y. Du, M. Luo, Y. Yu, W. Zhang, W. Lu
Journal: Annals of Oncology (2024)
300P Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with &gt;20-year follow-up
Authors: J. Tutzauer, J.K.J. De Vos, A. Nordenskjöld, B.A. Nordenskjöld, T. Fornander, G. Pérez Tenorio, O. Stål, N.P. Tobin, L.S. Lindström
Journal: Annals of Oncology (2024)
391P Real-world activity of sacituzumab govitecan for metastatic breast cancer
Authors: S. Morganti, R. Kusmick, M.E. Hughes, F. Brasó-Maristany, K. Smith, P. Tarantino, M.D.R. Vega León, T. Grinda, F. Pardo, K. Dvir, G. Suggs, S. Buck, M. Skeffington, A.C. Garrido-Castro, H. Parsons, S. Sammons, A. Prat, N. Lin, S.M. Tolaney, A. Giordano
Journal: Annals of Oncology (2024)
65O Cancer treatment monitoring using cell-free DNA fragmentomes
Authors: R. Fijneman, L. Rinaldi, Z. Skidmore, B. Alipanahi, L. Keefer, I. van 't Erve, K. Lumbard, J. Carey, B. Chesnick, S. Cristiano, N. Dracopoli, R. Scharpf, G. Meijer, A.I.C. Leal, V. Velculescu
Journal: Annals of Oncology (2024)
71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial
Authors: S-E. Bentebibel, D. McGrail, R. Abdel Wahab, V. Kochat, E. Arslan, B. Pazdrak, N.H. Tahon, R.N. Amaria, I.C. Glitza, S. Patel, M.K.K. Wong, H.A. Tawbi, J. Mcquade, M. Davies, C. Bernatchez, J. Burks, K. Rai, S. Ekmekcioglu, L. Lizée, A. Diab
Journal: Annals of Oncology (2024)
284P Clinical and molecular characteristics of early-stage triple-negative breast cancer (eTNBC) patients with germline pathogenic variants in homologous recombination repair genes
Authors: A. Rodriguez Hernandez, B. Conte, F. Braso Maristany, B. Pastor, B. Fratini, B. Walbaum, M. Potrony, L. Moreno, E. Grau, E. Sanfeliu Torres, O. Martinez Saez, E. Segui Solis, R. Gómez Bravo, I. Garcia Fructuoso, M.J. Vidal Losada, T. Ramon y Cajal, M. Munoz, F. Balaguer, A. Prat, B. Adamo
Journal: Annals of Oncology (2024)
76P Improving access to whole genome sequencing for patients with cancer of unknown primary using formalin-fixed paraffin embedded tissues and cell-free DNA
Authors: R.W. Tothill, R. Rebello, A. Posner, C. Mitchell, R. Dong, O. Prall, T. Sivakumaran, C. Mitchell, J. Vissers, A. Fellowes, H. Xu, H. Wong, D.D.L. Bowtell, S. Fox, P. Schofield, S-J. Dawson, P. Priestley, O. Hofmann, S.M. Grimmond, L. Mileshkin
Journal: Annals of Oncology (2024)
320MO Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study
Authors: X. Hu, Z. Tao, S. Wang, J. Zhang, Q. Zheng, Y. Wang, L. Cai, H. Xu, X. Xu, X. Kong, S. Ding, C. Hao, H. Wang, H. Zong, X. Jin, X. Wang, Y. Li, X. Yang, L. Ding, P. Li
Journal: Annals of Oncology (2024)
24P Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Authors: N. Bayat, V. Raúl, L. Martínez Gomez, C. Fernández Rozadilla, S. Abe, S-I. Tago, M. Fuji, A. Fernandez Montes, J. Garcia Mata, S. Georgescu
Journal: Annals of Oncology (2024)
58P Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
Authors: C. Yoo, A. Saborowski, J. Hyung, P. Wenzel, I. Kim, H. Wege, K-P. Kim, G. Folprecht, B-Y. Ryoo, P. Schütt, J. Cheon, T.O. Goetze, H. Ryu, J.S. Lee, A. Vogel
Journal: Annals of Oncology (2024)
47P First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study
Authors: S. Qin, T. Liang, S. Gu, H. Gou, C. Peng, Y. Pan, T. Song, H. Su, K. Cao, H. Liang, J. Ying, Z. Geng, W. Yu, H. Zhao, Y. Bai, C-Y. Hao, W. Wang, N. Li, U. Malhotra, Z. Ren
Journal: Annals of Oncology (2024)
22P Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Authors: R.I. Mülfarth, J. Lutz, R.K. Feist, K. Wolter, J. Krüger, M. Barends Cabello, J. Bauer, J.S. Walz, R. Heidenreich
Journal: Annals of Oncology (2024)
275P Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer
Authors: T. Luo, J. Chen, B. Wei, H. Shi, P. He, Q. Lv, X. Zhong, D. Zheng, C. Zhuang, K. Zhu, X. Yan, Y. Tian
Journal: Annals of Oncology (2024)
70MO Cell-free DNA indicates potential preclinical detectability of cancer signals up to 30 months prior to diagnosis
Authors: C.M. Vachon, R. Jiang, J. Youngren, E.T. Fung, E. Hubbell, O. Venn, X. Hou, K.V. Giridhar, F.J. Couch, B.A. Rybicki, R.L. Korn, Z. Alhilli, D. Kurbegov
Journal: Annals of Oncology (2024)
55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
Authors: A. Vogel, D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, A. Kuzko, J. Wang, I. Xynos, J.W. Valle
Journal: Annals of Oncology (2024)
238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
Authors: F. Cherifi, L. Cabel, C. Bousrih, E. Volant, F. Dalenc, B. Mery, M. Auvray Kuentz, M. Alexandre, L. Benistant, M. Leheurteur, C. Bailleux, M. Debled, J-S. Frenel, D. Loirat, F.C. Bidard, S. Aho, A. Glenet, J.T.L. Ribeiro Mourato, F. Christy, G. Emile
Journal: Annals of Oncology (2024)
73MO Longitudinal probing of combinatorial immunotherapy (anti-VEGF/anti-PD1) response in advanced nasopharyngeal carcinoma, at single cell resolution
Authors: S. Chia, N. Shirgaonkar, Y.C. Lim, J.K. Tay, W.Q. Chong, J.L. Low, K. Sooi, R.A. Soo, H.L. Teo, J. Samol, G. Goh, L.R. Kong, A. Gopinathan, D. Eu, R. Tsang, K-S. Loh, B.C. Tai, H.C. Toh, B-C. Goh, R. DasGupta
Journal: Annals of Oncology (2024)
72MO Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone
Authors: J. Braden, J.W. Conway, A. Ramanathan, L.A. Smith, A.M. Menzies, M.S. Carlino, G. Au-Yeung, R. Rawson, K.F. Shannon, T.E. Pennington, S. Ch'ng, R.P.M. Saw, A.J. Spillane, D. Gyokri, J. Howle, J. Wilmott, R.A. Scolyer, G.V. Long, I. Pires da Silva
Journal: Annals of Oncology (2024)
53P Envafolimab and chidamide in combination with GEMOX as first-line treatment for advanced and metastatic biliary tract cancer (B-Enefits/SCOG-B001): A single-arm, exploratory, phase II trial: Interim report
Authors: W. Li, K. Chen, X. Chen, D. Wang, M. Wu, C. Xu, K. He, M. Xu, B. Wang
Journal: Annals of Oncology (2024)
348MO A phase Ib/II study to assess the safety and efficacy of PM8002/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancer
Authors: J. Wu, J. Zhang, Z. Tong, Q. Zhang, Y. Wang, Q. Cheng, X. Chen, Z. Li, Y. Yin, Y. Du, Y. Meng
Journal: Annals of Oncology (2024)
49P Prognostic relevance of baseline exosome-delivered PD-1, PD-L1, pan-BTN3As and BTN3A1 in advanced cholangiocarcinoma patients: Can immune checkpoints act as a sentinel for predicting survival?
Authors: L.R. Corsini, D. Fanale, C. Brando, U. Randazzo, V. Spinnato, R. Polizzotto, T.D. Bazan Russo, P. Ferraro, O. Prestifilippo, G. Busuito, G.G. Frattallone, V. Gennusa, A. Perez, E. Pedone, M. Bono, L. Incorvaia, G. Badalamenti, A. Galvano, A. Russo, V. Bazan
Journal: Annals of Oncology (2024)
351P Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial
Authors: G. Bianchini, M. Martin Jimenez, S. Graff, R. Jeselsohn, S. Wander, R. Layman, S.A. Hurvitz, E.P. Hamilton, S. Sammons, P. Kaufman, H. Knoderer, B. Nguyen, Y. Zhou, E. Ravenberg, L. Litchfield, K. Kalinsky
Journal: Annals of Oncology (2024)
35P The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates
Authors: J. Ma, X. Guo, C. Lee, F. Meric-Bernstam, O. Harismendy, A. Jubb, D. Kim, M.R. Lackner
Journal: Annals of Oncology (2024)
322P Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021
Authors: A. Thomas, A. Rhoads, S. O'Reilly, E. Mayer, N. Harbeck, G. Curigliano, Y. Zhou, V.S. Adam, N. Chan, A. DeMichele, M. Ignatiadis, K. Kalinsky, P.A. Romitti
Journal: Annals of Oncology (2024)
245P Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Authors: P. Tarantino, H.S. Rugo, G. Curigliano, J. O'Shaughnessy, W. Janni, K. Jhaveri, J.A. Mouabbi, A.M. Brufsky, E.P. Hamilton, R. ORegan, E.C. Santarsiero, E. Sum, A. Scotchmer, F. Ye, S. Graff
Journal: Annals of Oncology (2024)
149P Evaluation of HLA genotype as predictive biomarker for immunological and clinical responses upon vaccination with PolyPEPI1018 cancer vaccine against colorectal cancer
Authors: J. Hubbard, L. Molnar, J. Toth, O. Lorincz, Z. Csiszovszki, E. Somogyi, E.R. Toke
Journal: Annals of Oncology (2024)
315P Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer
Authors: O. Danielsson, H.A. Dar, A. Nordenskjöld, G. Pérez Tenorio, C. Yau, C. Benz, L.J. Van't Veer, L. Esserman, B.A. Nordenskjöld, T. Fornander, O. Stål, N.P. Tobin, A. Johansson, L.S. Lindström
Journal: Annals of Oncology (2024)
18P The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
Authors: S. Lobo, A. Dias, M. Ferreira, J. Herrera-Mullar, M. Svrcek, R. Hueneburg, L. Moreira, S. Tinschert, L. Boussemart, J. Balmaña, V. Strong, C. Lazaro, B. Katona, C. Colas, F. Coulet, R. Karam, P.S. Pereira, P.R. Benusiglio, C. Oliveira
Journal: Annals of Oncology (2024)
239MO TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
Authors: M.V. Dieci, G. Bisagni, S. Bartolini, A. Schirone, L. Cavanna, A. Musolino, F. Giotta, A. Rimanti, O. Garrone, None E. bertone, K. Cagossi, S. Sarti, A. Ferro, F. Piacentini, E. Orvieto, M. Sanders, F. Miglietta, S. Balduzzi, R. D'Amico, V. Guarneri
Journal: Annals of Oncology (2024)
66O Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers
Authors: J.J. Sacco, R.D. Carvajal, O. Hamid, P.B. Kirk, L. Collins, M.O. Butler, A.N. Shoushtari, J.C. Hassel, A.P. Ikeguchi, L. Hernandez-Aya, P. Nathan, J.M. Piulats Rodriguez, H. Shaw, D. Davar, C. Han, M.R. Middleton, F. Thistlethwaite, F. Peck, K. Ranade, T. Sato
Journal: Annals of Oncology (2024)
150P Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers
Authors: A.R. Abdul Razak, A. Naing, A.N. Diep, C.C. Hwang, A.C. Reisetter, Z.L. Fuller, C. Hom, D.M. Glatt, M. Schmidt
Journal: Annals of Oncology (2024)
48P Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study
Authors: M.P.F. Quitadamo, A. Spallanzani, F. Gelsomino, B. Riccò, S. Cerri, E. Caffari, B. Medici, C. Petrangelo, F. Siciliano, L. Di Marco, S. Benatti, G. Luppi, M. Dominici, M. Salati
Journal: Annals of Oncology (2024)
27P Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Authors: E. Andreucci, A. Biagioni, P. Nardini, M. Lulli, A. Laurenzana, E. Gambale, L. Doni, L. Antonuzzo, S. Pillozzi, C. Talamonti, M. Mangoni, L. Magnelli, L. Papucci, L. Calorini
Journal: Annals of Oncology (2024)
158P Patterns of immune-related adverse events in early-phase cancer immunotherapy trials
Authors: B.P. Fairfax, V.C. Schmid, D.F. Lamparter, T. Kam-Thong, P. Scepanovic, G. Duchateau-Nguyen, A. Roller, R. Mohindra, V. Karanikas, D. Heinzmann, C. Adams, S.L. Mycroft, N. Städler
Journal: Annals of Oncology (2024)